Skip to main content
Premium Trial:

Request an Annual Quote

Tecan Starts Additional Share Buyback Program

NEW YORK (GenomeWeb News) – On the heels of a just-completed share repurchase program, Tecan has initiated another stock buyback program on the SWX Swiss Exchange.
Männedorf, Switzerland-based Tecan said today that it has completed its share repurchase program on the “first trading line,” which began Jan. 9, 2007, on the SWX Swiss Exchange. During that program, the firm bought 627,287 shares, or 5.2 percent of its share capital.
Tecan said it now owns 1,045,310 — or 8.65 percent — of its share capital.
The laboratory instrument firm will now embark on a second buyback program on a "second trading line," after which the shares will be cancelled and the share capital will be reduced accordingly. It said the program is limited to a maximum of 10 percent of the firm’s share capital.
Thomas Bachmann, CEO of Tecan, said that fiscal year 2007, “with the marked increase in profitability and our strong cash position put us in a position that allows us to pay back excess cash to our shareholders.”

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.